JP2011516497A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516497A5
JP2011516497A5 JP2011503214A JP2011503214A JP2011516497A5 JP 2011516497 A5 JP2011516497 A5 JP 2011516497A5 JP 2011503214 A JP2011503214 A JP 2011503214A JP 2011503214 A JP2011503214 A JP 2011503214A JP 2011516497 A5 JP2011516497 A5 JP 2011516497A5
Authority
JP
Japan
Prior art keywords
formulation
botulinum toxin
liposome
bladder
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011503214A
Other languages
English (en)
Japanese (ja)
Other versions
JP5538359B2 (ja
JP2011516497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/039489 external-priority patent/WO2009139984A2/en
Publication of JP2011516497A publication Critical patent/JP2011516497A/ja
Publication of JP2011516497A5 publication Critical patent/JP2011516497A5/ja
Application granted granted Critical
Publication of JP5538359B2 publication Critical patent/JP5538359B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011503214A 2008-04-04 2009-04-03 リポソームボツリヌス毒素を使用する膀胱機能障害の治療 Expired - Fee Related JP5538359B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4253608P 2008-04-04 2008-04-04
US61/042,536 2008-04-04
US11026608P 2008-10-31 2008-10-31
US61/110,266 2008-10-31
PCT/US2009/039489 WO2009139984A2 (en) 2008-04-04 2009-04-03 Method of treatment for bladder dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014000235A Division JP2014062125A (ja) 2008-04-04 2014-01-06 リポソームボツリヌス毒素を使用する膀胱機能障害の治療

Publications (3)

Publication Number Publication Date
JP2011516497A JP2011516497A (ja) 2011-05-26
JP2011516497A5 true JP2011516497A5 (enExample) 2011-12-08
JP5538359B2 JP5538359B2 (ja) 2014-07-02

Family

ID=41319235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011503214A Expired - Fee Related JP5538359B2 (ja) 2008-04-04 2009-04-03 リポソームボツリヌス毒素を使用する膀胱機能障害の治療
JP2014000235A Withdrawn JP2014062125A (ja) 2008-04-04 2014-01-06 リポソームボツリヌス毒素を使用する膀胱機能障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014000235A Withdrawn JP2014062125A (ja) 2008-04-04 2014-01-06 リポソームボツリヌス毒素を使用する膀胱機能障害の治療

Country Status (10)

Country Link
US (1) US20120093920A1 (enExample)
EP (2) EP2273976A2 (enExample)
JP (2) JP5538359B2 (enExample)
KR (1) KR20100131471A (enExample)
CN (1) CN102065841A (enExample)
AU (1) AU2009246834B2 (enExample)
BR (1) BRPI0911098A2 (enExample)
CA (1) CA2720523C (enExample)
MX (1) MX2010010635A (enExample)
WO (1) WO2009139984A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
RU2657591C2 (ru) 2012-08-31 2018-06-14 ТАРИС Биомедикал ЛЛК Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения
KR102383496B1 (ko) 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
CA2927356C (en) 2013-10-22 2022-08-23 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes
US20160045623A1 (en) 2015-04-03 2016-02-18 Lipella Pharmaceuticals, Inc. Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)
WO2019023388A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
PE20210041A1 (es) 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
KR102398743B1 (ko) * 2020-09-03 2022-05-16 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
TWI760996B (zh) * 2020-12-25 2022-04-11 姜秉均 含有疏水性物質的奈米組成物及其製備方法與用途
CN117883383A (zh) * 2023-12-26 2024-04-16 中国康复研究中心 一种作为A型肉毒素载体的TiO2纳米粒子及制备方法
US12272439B1 (en) 2024-05-06 2025-04-08 Immunitybio, Inc. Distributed ledger for medicament administration tracking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
AU2003259246A1 (en) 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
EP1933813A4 (en) * 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER

Similar Documents

Publication Publication Date Title
JP2011516497A5 (enExample)
ES2821098T3 (es) Preparaciones de hidrogel térmico reversible para su uso en el tratamiento de trastornos del urotelio
JP2008044951A5 (enExample)
CN101829036B (zh) 口腔喷雾剂
JP2002507548A (ja) 上気道状態を治療するためのキシリトール調合物
MX2008011823A (es) Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
JP2015513309A5 (enExample)
ATE511847T1 (de) Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes
JP2010513487A5 (enExample)
JP2013513612A5 (enExample)
AR070835A1 (es) Nueva dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios
WO2020043185A1 (zh) 氨基酸类营养素的应用以及包含它的药物组合物
JP2011503044A5 (enExample)
WO2014135891A1 (en) Pharmaceutical compositions for rectal administration
PT106094A (pt) Administração por inalação de formulações com dose elevada
US20200352986A1 (en) Methods and compositions for alleviating respiratory dysfunction
WO2009045145A1 (en) Novel compounds for the treatment or alleviation of edema, and methods for their use
JP2009522376A5 (enExample)
JP2009503097A5 (enExample)
CN102648279A (zh) 用于治疗药物诱发的手足综合征的组合物与方法
WO2008051527A3 (en) Sustained release of agents for localized pain management
Attia et al. Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway
Bowe et al. Therapeutic update: acne
JP2015518000A5 (enExample)
JP2025516040A (ja) 鼻腔内バクロフェン